Hi Joe, A very interesting issue! Lots of interesting economics and dynamics in there ... and interesting stories too! (Even some good ones like Gerber continuing to make their 'meat substitute' babyfood - even at a loss - because it helps some kids with an unusual condition.) * If your new cure is 'too' effective, you eliminate your market need before you recoup your R&D expenses. * If 'too few' people suffer from a malady, it isn't cost effective to even research a cure. RonL. (Hey! Did I tell you about the time I tried to sell Marketing (at the telco) on an ad campaign showing the benefits custom calling services would have for organized crime? Call Waiting: "... yeah, I'll take 20 kilos" (BEEP) "... wait a minute, another call coming in" <click> "Yeah?" "Cheese it, Tony! The heat!" :-) ) -----Original Message----- From: Joe Crawford [mailto:jcrawford at avencom.com] Subject: Re: [thechat] pure evil: Tobacco giant buys rights to lung cancer drugs The natural tension is between two things -- the ability of people who develop cures to reap a benefit from the work put in to developing those cures (and hopefully grow enough to get more) -- and the ability of the sick to get access to those cures. There's a similar problem in the drug industry.